Shattuck Labs, Inc. Overview
Pro stress-test →Shattuck Labs is a biotechnology company developing antibodies for the treatment of inflammatory and immune-mediated diseases. The company is pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies. As a clinical-stage biotech with $86M in cash (Q3 2025), Shattuck is advancing its lead candidate SL-325 through Phase 1 trials targeting inflammatory bowel disease (IBD).
Strategic Profile
Pro stress-test →The company's lead asset SL-325 is being advanced through multiple Phase 2 clinical trials focusing on Inflammatory Bowel Disease (IBD). Shattuck closed a private placement of up to $103 million in August 2025 expected to fund operations into 2029. The company is strategically positioned in the high-potential TNF superfamily receptor pathway with experienced leadership additions from J&J/Janssen and OrbiMed.
Competitive Landscape
Pro stress-test →Shattuck competes in the immunology/IBD therapeutics space against major pharma (Janssen, Gilead, AbbVie) and emerging biotech (Foghorn Therapeutics, C4 Therapeutics). Its differentiation rests on the first-in-class DR3 mechanism and bispecific platform enabling combination potential. Market size and clinical validation of TNF pathways provide tailwinds.
Industry Context
Shattuck Labs, Inc. operates in Biopharmaceuticals / Clinical-Stage Immunology.
Key facts
Founded: 2016 · Headquarters: Austin, US · Employees: 44 · Market cap: $286.66M